Financial Comparison: Xeris Biopharma (NASDAQ:XERS) versus Organon & Co. (NYSE:OGN)

Xeris Biopharma (NASDAQ:XERS) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

42.7% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 4.3% of Xeris Biopharma shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Xeris Biopharma and Organon & Co.”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85 million	6.37	$550,000.00	($0.11)	-92.73
Organon & Co.	$6.22 billion	0.58	$187.00 million	$0.77	17.89

Organon & Co. has higher revenue and earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Xeris Biopharma and Organon & Co., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1	2	4	0	2.43
Organon & Co.	2	5	0	0	1.71

Xeris Biopharma currently has a consensus target price of $13.20, indicating a potential upside of 29.41%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 17.24%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Organon & Co..

Volatility and Risk

Xeris Biopharma has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares Xeris Biopharma and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Organon & Co.	3.41%	88.97%	6.03%

Summary

Organon & Co. beats Xeris Biopharma on 8 of the 14 factors compared between the two stocks.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.